Postdoctoral Fellow - Clinical Cancer Prevention (Dr. Guang Peng)
- The University of Texas M. D. Anderson Cancer Center
- Location: Houston, TX
- Job Number: 7076751 (Ref #: Peng0405)
- Posting Date: Apr 5, 2021
- Application Deadline: Open Until Filled
Job DescriptionThe Department of Clinical Cancer Prevention (CCP), The Department of Genitourinary Medical Oncology (GMO) and The Department of Investigational Cancer Therapeutics (ICT)- Research at MD Anderson Cancer Center have multiple post-doc positions open for studying genomic instability, anti-tumor immunity and immunotherapy in a collaborative research group led by Dr. Guang Peng (CCP), Dr. Eric Jonasch (GMO) and Dr. Timothy Yap (ICT). Their laboratory and clinical research studies focus on utilizing genetic, proteomic, and chemical approaches to understand the DNA damage response and repair network and develop preventive/therapeutic strategies to harness anti-tumor immunity by targeting the DNA repair network through the interconnected adaptive (neo-antigen/mutanome dependent) and innate (neo-antigen/mutanome-independent) immune responses. A variety of cell models, animal models and disease models will be used including kidney, ovarian and breast cancers.
The post-doc will work in an extremely collaborative and supportive environment with mentoring and supervision from both a basic research scientist (Dr. Peng) and physician-scientists (Dr. Jonasch and Dr. Yap). Our recently funded biological projects (R01, DODs and private foundations) with both mechanistic and translational significance may impact both cancer prevention and therapy and the candidate will have the opportunity to publish in high-impact journals.
Selected recent publications related to the projects for this postdoc position from our research group:
Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih IeM, Uray IP, Wu X, Brown PH, Shen X, Mills GB, Peng G. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 2015 Jul;5(7):752-67. PMID: 26069190; PMCID: PMC4497871 (Cancer Discovery Cover Story)
Jianfeng Shen, Zhenlin Ju, Wei Zhao, Lulu Wang, Yang Peng, Zhongqi Ge, Zachary D. Nagel, Jun Zou, Chen Wang, Prabodh Kapoor, Xiangyi Ma, Ding Ma, Jiyong Liang, Shumei Song, Jingsong Liu, Leona D. Samson, Jaffer A. Ajani, Guomin Li, Han Liang, Xuetong Shen, Gordon B. Mills, and Guang Peng. ARID1A deficiency promotes mutability and potentiates anti-tumor immunity unleashed by immune checkpoint blockade. Nature Med. 2018 May;24(5):556-562. PubMed PMID: 29736026; PMCID: PMC6076433.
Hsieh H, Zhang W, Lin S, Yang W, Wang J, Shen J, Zhang Y, Lu Y, Wang H, Yu J, Mills G, Peng G. Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. Nat Commun. 2018 Sep 28;9(1):3982. PMID:30266942; PMCID: PMC6162282.
Shen J, Zhao W, Ju Zhenlin, Wang L, Peng Y, Labrie M, Yap T, Mills G, Peng G. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Research. 79 (2):311-319, 01/2019. PMID:30482774
Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, Clemens A, Luu Yen T, Song S, Yap T, Ajani J, Mills G, Shen X, Peng G. Inhibition of the ATM-Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest. 2020 130(11):5951-5966. PMID: 33016929
Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell, WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020 May 1;11(1):2135 PMID: 32358509
Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 6/2020. PMID: 32568634.
Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris N, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discovery, 9/2020. PMID: 32988960.
Yap TA, Kristeleit R, Michalarea V, Pettitt SJ Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodriguez DN, Ward S, Mattews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Fozley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers. Cancer Discov 10(10):1528-1543, 10/2020. PMID: 3253274
The primary research focus will be conducting genomic instability research using in vitro experimental methods for the mechanistic studies. The fellow will also gain extensive experience in preclinical animal models, clinical specimen validation and bioinformatic analysis using the TCGA database and chemical compounds’ databases.
We seek a highly motivated individual with a Ph.D. in molecular biology/cancer biology.
Diversity and inclusion at MD Anderson are not just important; they are essential. We take an expansive view of diversity, considering differences in race, ethnicity, sexual orientation, gender and religious beliefs, as well as communication styles, thought, skill and ambition. We constantly examine our culture to create an inclusive working environment that effectively attracts, retains, develops and utilizes the skills and talents of all employees. Our Diversity Council develops strategies to attract and retain superior talent and enhance workforce diversity and inclusion. We also offer multiple diversity training programs to our employees.